Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,112 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of baseline levels of markers of bone and cartilage degradation with long-term progression of joint damage in patients with early rheumatoid arthritis: the COBRA study.
Garnero P, Landewé R, Boers M, Verhoeven A, Van Der Linden S, Christgau S, Van Der Heijde D, Boonen A, Geusens P. Garnero P, et al. Among authors: van der heijde d, van der linden s. Arthritis Rheum. 2002 Nov;46(11):2847-56. doi: 10.1002/art.10616. Arthritis Rheum. 2002. PMID: 12428224 Free article. Clinical Trial.
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial.
Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Klareskog L, et al. Among authors: van der heijde d. Lancet. 2004 Feb 28;363(9410):675-81. doi: 10.1016/S0140-6736(04)15640-7. Lancet. 2004. PMID: 15001324 Clinical Trial.
Markers for type II collagen breakdown predict the effect of disease-modifying treatment on long-term radiographic progression in patients with rheumatoid arthritis.
Landewé R, Geusens P, Boers M, van der Heijde D, Lems W, te Koppele J, van der Linden S, Garnero P. Landewé R, et al. Among authors: van der heijde d, van der linden s. Arthritis Rheum. 2004 May;50(5):1390-9. doi: 10.1002/art.20222. Arthritis Rheum. 2004. PMID: 15146408 Free article. Clinical Trial.
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J; Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group. van der Heijde D, et al. Arthritis Rheum. 2005 Feb;52(2):582-91. doi: 10.1002/art.20852. Arthritis Rheum. 2005. PMID: 15692973 Free article. Clinical Trial.
Low-dose prednisolone in addition to the initial disease-modifying antirheumatic drug in patients with early active rheumatoid arthritis reduces joint destruction and increases the remission rate: a two-year randomized trial.
Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafström I. Svensson B, et al. Among authors: van der heijde d. Arthritis Rheum. 2005 Nov;52(11):3360-70. doi: 10.1002/art.21298. Arthritis Rheum. 2005. PMID: 16255010 Free article. Clinical Trial.
1,112 results